Literature DB >> 19605950

Effect of interleukin 6 deficiency on the expression of Bcl-2 and Bax in the murine heart.

Karol A Kamiński1, Marcin Kozuch, Tomasz A Bonda, Maria M Stepaniuk, Ewa Waszkiewicz, Lech Chyczewski, Włodzimierz J Musiał, Maria M Winnicka.   

Abstract

Interleukin 6 (IL-6) is a pleiotropic cytokine that is highly expressed in response to ischemia and reperfusion. It has dichotomous roles in the heart, functioning both as an inflammatory mediator as well as a protective agent. The aim of this study was to evaluate the effect of IL-6 deficiency on the expression of apoptotic regulatory proteins under both baseline conditions and following induction of ischemia and reperfusion in the mouse heart. C57BL/6J IL-6-/-(TMKopf) (IL6KO) and C57BL/6J mice (WT) were subjected to 30 minutes of local reversible myocardial ischemia in vivo or a sham operation. The expression of Bcl-2, Bax and STAT3 in the heart was assessed by western blotting. Under both baseline conditions and following the sham operation, IL-6 deficiency was associated with reduced expression of Bcl-2 and Bax. The TUNEL-FITC, Evans blue and tetrazolium chloride staining of the hearts following ischemia and reperfusion revealed similar injury in operated IL6KO and WT animals. There was increased STAT3 phosphorylation in operated mice regardless of the genotype. Bcl-2 and Bax expression was also comparable between the mouse strains following ischemia and reperfusion. In summary, these results indicated that IL-6 deficiency affected the basal expression of apoptotic regulators, but this did not profoundly alter the extent of reperfusion injury or apoptosis in the mouse heart following ischemia and reperfusion.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19605950     DOI: 10.1016/s1734-1140(09)70093-3

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  6 in total

1.  Interleukin-8 blockade prevents activated endothelial cell mediated proliferation and chemoresistance of acute myeloid leukemia.

Authors:  Vindhya Vijay; Regan Miller; Gau Shoua Vue; Mida Bahareh Pezeshkian; Michael Maywood; Allison M Ast; Leylah M Drusbosky; Yuri Pompeu; Alan D Salgado; Samuel D Lipten; Timothy Geddes; Ann Marie Blenc; Yubin Ge; David A Ostrov; Christopher R Cogle; Gerard J Madlambayan
Journal:  Leuk Res       Date:  2019-07-03       Impact factor: 3.156

2.  Interleukin-6: A Constitutive Modulator of Glycoprotein 130, Neuroinflammatory and Cell Survival Signaling in Retina.

Authors:  Franklin D Echevarria; Abigayle E Rickman; Rebecca M Sappington
Journal:  J Clin Cell Immunol       Date:  2016-07-22

Review 3.  An Overview of the Molecular Mechanisms Associated with Myocardial Ischemic Injury: State of the Art and Translational Perspectives.

Authors:  Leonardo Schirone; Maurizio Forte; Luca D'Ambrosio; Valentina Valenti; Daniele Vecchio; Sonia Schiavon; Giulia Spinosa; Gianmarco Sarto; Vincenzo Petrozza; Giacomo Frati; Sebastiano Sciarretta
Journal:  Cells       Date:  2022-03-30       Impact factor: 6.600

4.  Meta-analysis reveals inhibition of the inflammatory cytokine IL-6 affords limited protection post-myocardial ischemia/infarction.

Authors:  Sushmitha Duddu; Mohan Agrawal; Rituparna Chakrabarti; Anuran Ghosh; Nishant Chakravorty; Ashutosh Tiwari; Praphulla Chandra Shukla
Journal:  Heliyon       Date:  2022-08-28

5.  Reduced acute myocardial ischemia-reperfusion injury in IL-6-deficient mice employing a closed-chest model.

Authors:  Willeke M C Jong; Hugo Ten Cate; André C Linnenbank; Onno J de Boer; Pieter H Reitsma; Robbert J de Winter; Coert J Zuurbier
Journal:  Inflamm Res       Date:  2016-03-02       Impact factor: 4.575

Review 6.  Inflammation following acute myocardial infarction: Multiple players, dynamic roles, and novel therapeutic opportunities.

Authors:  Sang-Bing Ong; Sauri Hernández-Reséndiz; Gustavo E Crespo-Avilan; Regina T Mukhametshina; Xiu-Yi Kwek; Hector A Cabrera-Fuentes; Derek J Hausenloy
Journal:  Pharmacol Ther       Date:  2018-01-09       Impact factor: 12.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.